In:
Frontiers in Endocrinology, Frontiers Media SA, Vol. 12 ( 2021-10-15)
Kurzfassung:
Papillary thyroid cancer (PTC) in clinically lymph node-negative (cN0) patients is prone toward lymph node metastasis. As a risk factor for tumor persistence and local recurrence, lateral lymph node metastasis (LLNM) is related to the number of central lymph node metastases (CLNMs). Methods We performed LLNM risk stratification based on the number of CLNMs for cN0 PTC patients who underwent thyroidectomy and lymph node dissection between January 2013 and December 2018. A retrospective analysis was applied to the 274 collected patients with 1-2 CLNMs. We examined the clinicopathological characteristics of the patients and constructed a LASSO model. Results In the 1–2 CLNM group, tumors & gt;10 mm located in the upper region and nodular goiters were independent risk factors for LLNM. Specifically, tumors & gt;20 mm and located in the upper region contributed to metastasis risk at level II. Hashimoto’s thyroiditis reduced this risk ( p = 0.045, OR = 0.280). Age ≤ 30 years and calcification (microcalcification within thyroid nodules) correlated with LLNM. The LASSO model divided the population into low- (25.74%) and high-risk (57.25%) groups for LLNM, with an AUC of 0.715. Conclusions For patients with 1–2 CLNMs, young age, calcification, nodular goiter, tumor & gt;10 mm, and tumor in the upper region should alert clinicians to considering a higher occult LLNM burden. Close follow-up and therapy adjustment may be warranted for high-risk patients.
Materialart:
Online-Ressource
ISSN:
1664-2392
DOI:
10.3389/fendo.2021.716728
DOI:
10.3389/fendo.2021.716728.s001
DOI:
10.3389/fendo.2021.716728.s002
DOI:
10.3389/fendo.2021.716728.s003
DOI:
10.3389/fendo.2021.716728.s004
DOI:
10.3389/fendo.2021.716728.s005
Sprache:
Unbekannt
Verlag:
Frontiers Media SA
Publikationsdatum:
2021
ZDB Id:
2592084-4
Permalink